Fact-checked by Grok 2 weeks ago

Extravasation

Extravasation is the leakage of intravenously administered fluids, including , , or medications, from a into the surrounding extravascular . In clinical settings, it most commonly occurs during intravenous () infusions when a becomes dislodged, a is punctured, or administration errors lead to the escape of vesicant drugs—agents capable of causing severe damage—such as certain . This phenomenon is particularly prevalent in , where up to 6% of infusions may result in extravasation, though incidence rates have declined to as low as 0.01% with improved protocols. The severity of extravasation varies based on the leaked substance's properties (e.g., , osmolarity, and vesicant potential), the volume extravasated, and patient factors like vein fragility in the elderly or those with compromised vasculature. Symptoms typically include immediate pain, stinging, burning, swelling, and at the site, progressing to blistering, induration, or in severe cases graded 3–5 on the Common Terminology Criteria for Adverse Events (NCI CTCAE). Risk factors encompass patient-related elements (e.g., , ), procedural issues (e.g., multiple cannulation attempts by untrained staff), and device failures (e.g., insecure fixation). Management prioritizes rapid intervention to minimize damage: immediately stopping the , attempting to aspirate residual , and applying antidotes like for or for alkaloids, alongside thermal compresses (cold for most vesicants, warm for others). of the affected limb and sterile dressings follow, with surgical consultation for high-risk or cases; recovery can range from days for mild incidents to months for extensive . Prevention strategies emphasize staff training, vigilant monitoring for patient-reported sensations, use of extravasation kits, and preferential central venous access for high-risk therapies.

Definition and Pathophysiology

Definition

Extravasation is defined as the leakage of intravenously administered fluids, medications, , or other substances from vessels into the surrounding extravascular s. It occurs when any intravenously administered substance escapes from a into the extravascular space, potentially leading to if the substance is a vesicant. The term "extravasation" derives from Latin roots "extra" meaning "outside" and "vas" meaning "vessel," combined with the suffix "-ation" to form a indicating the process. It first appeared in in the late , with the earliest recorded use in 1676 by English surgeon to describe the escape of fluids from s. Extravasation is distinguished from infiltration, a broader term for the general leakage of any intravenous fluid into surrounding tissues without causing harm; in contrast, extravasation specifically refers to the infiltration of potentially damaging agents, such as vesicants or chemotherapeutic drugs, which can result in tissue destruction. While most commonly associated with intravenous therapy, the term also applies more generally to scenarios like hemorrhage, where blood leaks from vessels, or urine extravasation in urological contexts.

Pathophysiology

Extravasation begins with disruption of vascular integrity, often due to dislodgement, vein wall puncture, or elevated that compromises endothelial barriers, allowing infusate to leak into surrounding perivascular tissues. This endothelial damage facilitates the efflux of fluids and agents into the interstitial space, initiating immediate hydrostatic buildup that exceeds tissue , resulting in localized and potential from fluid accumulation. The tissue response unfolds in phases, starting with acute hydrostatic that distends local structures and impairs . This rapidly progresses to an inflammatory response with immune cell infiltration, which can exacerbate swelling and lead to in severe cases. Agent-specific effects contribute variably to damage; hypertonic solutions create osmotic imbalances that draw water from cells, causing intracellular dehydration, shrinkage, and . Vesicant agents, such as certain chemotherapeutics or alkaline drugs, induce chemical through direct cytotoxicity, including protein denaturation and DNA binding that generates free radicals, promoting and . For instance, like intercalate into DNA, leading to strand breaks and prolonged cellular toxicity. Key cellular events include infiltration driven by chemotactic signals from the inflammatory milieu, which releases additional enzymes and , intensifying local damage through further free radical production and . This amplifies ischemia and , particularly in vasoconstrictive extravasations where alpha-adrenergic stimulation reduces blood flow, compounding hypoxic injury.

Causes and Risk Factors

Primary Causes

Extravasation primarily occurs in medical settings due to procedural errors during intravenous (IV) , where the unintended leakage of infused substances from veins into surrounding tissues arises from issues such as migration, improper insertion, or disconnection. migration can result from movement or inadequate securing, allowing the device to dislodge from the vessel wall and permit fluid efflux. Improper insertion, including piercing through the vein or selecting unsuitable sites, similarly compromises vascular integrity, while disconnections during infusion exacerbate the risk by enabling free leakage. Infusate-related causes involve the mechanical forces of administration that overwhelm vessel capacity, particularly during high-pressure infusions of viscous fluids, which can lead to vessel rupture or dislodgement. For instance, power injectors used for contrast media in imaging studies apply pressures up to 300 psi, potentially causing endothelial damage and leakage, with a reported incidence of approximately 0.2% in computed tomography procedures. Similarly, in chemotherapy administration, rapid or high-volume infusion of vesicant agents like doxorubicin can generate sufficient pressure to breach vessel walls, though the primary trigger remains the infusion dynamics rather than the agent's toxicity alone. In surgical contexts, extravasation often stems from the use of fluids under pressure, as seen in procedures where fluid extravasates into periarticular tissues through capsular defects or venous channels. Shoulder , for example, frequently involves fluid volumes exceeding 2 liters, leading to subcutaneous, muscular, or even pleural accumulation that can compromise airway patency if unmanaged. Non-IV causes include -induced vessel damage, which disrupts vascular continuity and allows fluid or blood extravasation, and spontaneous occurrences in inflammatory conditions like . Blunt or to the , such as from pelvic fractures, can cause rupture and urinary extravasation into surrounding pelvic tissues, manifesting as scrotal or perineal swelling. In , such as , immune-mediated weakens vessel walls, promoting spontaneous leakage of plasma and red blood cells into tissues, resulting in or without external .

Risk Factors

Risk factors for extravasation can be categorized into patient-related, procedural, and environmental elements, each contributing to the increased likelihood of intravenous fluid or medication leakage into surrounding tissues. Patient-related factors often involve inherent vulnerabilities in vascular integrity, such as fragile veins commonly seen in elderly individuals due to age-related thinning of and vessel walls, pediatric patients with immature vasculature, and obese patients where excess obscures vein visualization and access. Conditions like peripheral further heighten this risk by compromising vein patency and resilience, while a history of intravenous drug use or multiple prior venipunctures can lead to sclerotic or scarred veins that are more prone to dislodgement. Procedural factors primarily stem from the choice and execution of vascular access techniques. The use of peripheral intravenous lines, as opposed to central venous access, significantly elevates extravasation risk, particularly when administering vesicant agents without optimal , such as avoiding areas with poor collateral circulation. Additionally, administration by inexperienced or untrained staff increases the incidence, as improper cannula insertion, securing, or monitoring can result in inadvertent dislodgement during infusion. Environmental and infusate-related factors include prolonged dwell times, which correlate with higher extravasation rates due to increased opportunities for or , and high-volume infusions that exert greater pressure on vessel walls. Certain infusates, such as hyperosmolar solutions with osmolarities exceeding 350 mOsm/L or extreme levels (<5 or >9), exacerbate tissue damage potential if extravasation occurs by drawing fluid into the and causing local irritation. Overall incidence of extravasation varies by context but is notably higher in settings, ranging from 0.1% to 6% of infusions, underscoring the compounded risks in patients receiving vesicant therapies.

Classification

By Infused Agent

Extravasation events are categorized according to the characteristics of the leaked substance, which determines the potential for injury. Agents are broadly divided into non-vesicant infusates that cause minimal damage, irritants that induce without , and vesicants that lead to severe and destruction. Other substances, such as certain hypertonic solutions or radiocontrast media, may exhibit properties overlapping these categories based on concentration and volume. Non-vesicant infusates, such as fluids like normal saline, typically result in negligible harm due to their compatibility with physiological osmolarity and , often manifesting only as localized swelling that resolves without intervention. In surgical contexts, fluids—commonly solutions used during procedures like —can lead to more significant complications if large volumes extravasate, potentially causing through increased intracompartmental pressure and impaired perfusion. For instance, extravasation volumes exceeding 10% of the infused amount during hip have been associated with in rare cases, necessitating prompt recognition to avoid ischemic injury. Irritant agents provoke local , , and along the vein without progressing to full-thickness , primarily due to their hypertonicity, acidity, or direct cellular . Common examples include certain antibiotics like , which can cause intense local discomfort and venous upon leakage, as well as solutions such as those containing calcium or magnesium that disrupt cellular membranes and induce . These effects are generally self-limiting with conservative measures, though repeated may exacerbate venous damage. Vesicant agents pose the highest risk, capable of inducing profound cytotoxicity through mechanisms such as DNA intercalation or microtubule disruption, leading to rapid cell death and progressive ulceration. Chemotherapeutic drugs exemplify this category: anthracyclines like doxorubicin bind to DNA, triggering apoptosis in local cells and releasing the agent from dying tissues to perpetuate damage in surrounding areas; vinca alkaloids such as vincristine interfere with mitotic spindles, causing endocytolysis and impaired wound healing. Vasopressors, including norepinephrine, act as vesicants by inducing severe vasoconstriction and ischemia in extravasated tissues, compounded by their alpha-adrenergic effects that exacerbate local hypoxia. These mechanisms distinguish vesicants from less damaging agents, as the injury often extends beyond the initial leak site due to secondary inflammation and fibrosis. Other agents include radiocontrast media, which can cause chemical burns and through osmotic effects and direct endothelial toxicity, particularly with high volumes (>50 mL) of ionic agents like , leading to and potential skin . Hypertonic solutions, such as concentrated , are similarly hazardous, precipitating protein denaturation and cell due to extreme osmolarity and ionic imbalance, resulting in severe and tissue even in small extravasated amounts.

By Tissue Damage Severity

Extravasation injuries are classified by the severity of damage to assess the extent of involvement, guide clinical management, and predict outcomes such as the potential for . This grading focuses on observable signs like , skin changes, pain levels, and functional impairment, rather than the properties of the infused agent. The Infiltration Scale is a widely adopted for evaluating these injuries, standardizing and based on the most severe presenting indicator. Higher grades indicate compromise, with vesicant extravasations more likely to progress to in grades 3 and 4. Grade 0 (): No symptoms of infiltration. Grade 1 (Mild): blanched; less than 1 inch (2.5 cm) in any direction; cool to the touch; with or without pain; no functional deficit. These injuries typically resolve spontaneously with site elevation and observation. Grade 2 (Moderate): blanched; 1 to 6 inches (2.5 to 15 cm) in any direction; cool to the touch; with or without ; no functional impairment. Conservative measures such as warm or compresses, , and are recommended. Grade 3 (Severe): blanched; gross greater than 6 inches (15 cm) in any direction; cool to the touch; mild to moderate ; possible numbness or functional deficits such as tightness or . With vesicants, these may progress to full-thickness or ulceration, requiring surgical evaluation and potential . Grade 4 (Life-Threatening): blanched and translucent; gross greater than 6 inches (15 cm) in any direction with deep pitting tissue ; tight or leaking; circulatory impairment; moderate to severe ; infiltration of any amount of blood products, irritant, or vesicant; obvious functional deficits including compromise of multiple tissue compartments or circumferential involvement. This can lead to or widespread , demanding urgent surgical intervention such as or reconstruction; such cases are rare but carry high morbidity. The INS scale facilitates early identification and escalation, complementing other systems like the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, which grades from painless (Grade 1) to skin necrosis or ulceration with of deep tissue (Grade 4). Consistent use of these tools improves outcomes by tailoring responses to the degree of tissue injury.

Clinical Presentation

Symptoms

Patients experiencing extravasation often report at the , characterized by burning, stinging, or a sensation of tightness, which may appear disproportionate to any immediately visible changes in the skin. This discomfort arises from the irritant effects of the leaked fluid on surrounding tissues and can intensify rapidly if the extravasated agent is a vesicant. Sensory alterations, such as numbness, tingling, or a feeling of coolness in the affected area, may occur due to edema-induced . These symptoms typically develop shortly after the onset of swelling and reflect local on sensory nerves. Early visible signs include localized swelling, , or surrounding the intravenous site, with potential progression to blistering in cases involving vesicant agents. Induration and taut skin may also manifest as the accumulates, sometimes accompanied by leakage of fluid from the site. Systemic symptoms are uncommon in the immediate phase but can include fever if an early complicates the extravasation. These manifestations, when present, underscore the need for prompt clinical evaluation, and symptoms overall may align with established severity grading systems for tissue damage.

Diagnostic Methods

of extravasation typically begins with clinical examination protocols to confirm the presence of infiltration beyond initial symptoms such as localized swelling. Healthcare providers perform and of the affected site to detect induration, which presents as a firm, hardened area in the indicative of fluid accumulation and potential tissue damage. Additionally, serial measurements of the limb's at the site of suspected extravasation are conducted to quantify swelling and monitor its progression, helping to differentiate extravasation from other causes of . To verify intravenous line patency and rule out extravasation, an test is routinely employed prior to and during infusions. This involves attaching a to the and gently aspirating for return, which confirms proper venous placement; absence of flow suggests possible or leakage. If return is obtained, a small flush of saline (1-2 mL) is administered while observing for resistance, pain, or increased swelling, further assessing integrity. Imaging modalities provide objective confirmation and evaluation of extravasation extent when clinical findings are equivocal. , particularly with color-flow Doppler, visualizes the vein and catheter tip in , detecting pockets or abnormal patterns with high (up to 100%) and specificity, enabling early identification of infiltration before significant involvement. In severe cases involving deep damage, (MRI) is utilized to assess the full scope of injury, revealing areas of decreased signal intensity on T1- and T2-weighted images along with contrast enhancement in affected subcutaneous and fascial layers, guiding surgical planning if necessary. No laboratory tests are specific to extravasation diagnosis, but in instances of suspected muscle involvement—such as when extravasation leads to compartment syndrome—serum creatine kinase (CK) levels are monitored for elevations indicative of rhabdomyolysis or myonecrosis. CK levels exceeding 4000 U/L correlate with muscle breakdown and aid in evaluating the severity of tissue injury.

Prevention Strategies

Vascular Access Best Practices

Vascular access best practices are essential for minimizing the risk of extravasation during peripheral placement and maintenance, focusing on procedural techniques that ensure proper cannulation and device stability. These practices emphasize selecting optimal insertion , appropriate selection, precise insertion methods, and routine management to reduce complications such as infiltration or leakage of infusates into surrounding tissues. Site selection plays a critical role in preventing extravasation by prioritizing veins that can accommodate the infusate volume and type while minimizing . Larger veins in the or upper arm of the non-dominant extremity are preferred, as they offer greater flow capacity and lower risk of dislodgement compared to smaller or distal hand veins. Sites should avoid areas near valves, joints, or flexion points, such as the antecubital fossa or , to prevent mechanical stress and potential leakage; additionally, fragile veins in patients with conditions like chemotherapy-induced damage increase extravasation risk and warrant avoidance when possible. Compromised sites, including those with , , or prior surgical intervention, must also be bypassed to maintain vessel integrity. Catheter selection should involve the smallest compatible with the prescribed to limit wall and facilitate secure placement. For example, 20- to 22- catheters are often suitable for most adult infusions, while larger gauges (18- or smaller numbers) are reserved for rapid fluid resuscitation. Post-insertion, catheters must be secured using transparent semi-permeable dressings combined with engineered stabilization devices to prevent movement (pistoning) at the insertion site, which can lead to extravasation; excessive tape should be avoided, as it may cause or allergic reactions without providing superior fixation. Insertion techniques further reduce extravasation risk through precise manipulation to ensure intraluminal placement. The should be stabilized with the non-dominant hand by applying gentle traction to straighten it, followed by needle insertion at a 15- to 30-degree angle with the facing upward to facilitate smooth entry and minimize backwall puncture. flashback in the chamber confirms venous , after which the angle is lowered, and the is advanced off the needle stylet before securing the device. Aseptic non-touch technique is mandatory throughout to avoid that could compromise the site. Adherence to established guidelines, such as those from the Infusion Nurses Society (INS) in their 2024 Standards of Practice and Centers for Disease Control and Prevention (CDC) guidelines, ensures these practices are evidence-based and consistently applied. Key recommendations include replacing peripheral IV sites when clinically indicated (e.g., due to complications like phlebitis or infiltration) or no more frequently than every 72 to 96 hours in adults. These protocols promote patient safety by integrating site assessment, device selection, and procedural precision.

Monitoring and Early Detection

Effective monitoring protocols for extravasation involve regular assessment of the infusion site to detect subtle changes before substantial tissue damage occurs. For high-risk infusions, such as those involving vesicant agents, the infusion site should be inspected after 15 minutes of initiation and subsequently every 4 hours until completion, with more frequent checks during active administration. In peripheral intravenous () settings for vesicant , nurses are recommended to remain at the bedside and verify blood return and patency every 5-10 minutes for intravenous piggyback infusions or every 2-5 mL infused for intravenous push administrations. Continuous visual monitoring using transparent dressings is advised to maintain site visibility throughout the infusion process. Key signs warranting immediate attention include resistance or slowed flow in the , absence of blood return upon , visible leakage at the site, and emerging local symptoms such as swelling or induration. plays a critical role, with instructions provided prior to to report any new pain, burning, or discomfort at the site without delay, enabling prompt intervention. This empowers patients to actively participate in surveillance, particularly during or home-based therapies. Technological aids enhance early detection by providing objective alerts for potential extravasation. Securement devices, such as engineered stabilization products, minimize dislodgement and support consistent site observation. Advanced sensors, including impedance-based patches that detect fluid accumulation through changes in electrical properties (with 100% at flow rates of 2.5-5 /s and minimum detectable volumes of approximately 3-13 ) and radiofrequency devices offering 99.8% at 20 , can trigger alarms to interrupt automatically. Optical and sensors further assist by visualizing position or detecting minimal volumes as low as 0.1 with high specificity. In settings, special considerations apply to vesicant , where protocols emphasize heightened vigilance due to the agents' potential for severe tissue necrosis. Guidelines recommend continuous bedside during peripheral of vesicants lasting under 60 minutes, with a preference for central venous access devices for longer infusions to reduce extravasation risk. Updated protocols from cancer centers, such as those from 2023, underscore pre-infusion patency checks and real-time flow rate to align with evolving standards.

Management and Treatment

Immediate Response

Upon suspicion of extravasation, the primary goal is to halt further leakage of the infused agent into the surrounding tissues to minimize potential damage. The first step is to immediately stop the infusion by occluding the intravenous line proximal to the insertion site, thereby preventing additional fluid from entering the affected area. The tubing should then be disconnected from the cannula, which is left in place to facilitate subsequent assessment and intervention without risking further tissue trauma. Following cessation of the , an attempt should be made to aspirate any residual extravasated fluid from the using a small , taking care not to enlarge the puncture site or apply excessive pressure that could exacerbate leakage. This aspiration is performed gently to withdraw as much of the leaked agent as possible, with the volume and description of the aspirate documented for clinical records. To reduce swelling and promote reabsorption of any extravasated fluid, the affected limb should be elevated above the level of the heart, which decreases hydrostatic pressure in the capillaries and limits edema formation. Elevation is maintained as tolerated by the patient, typically for the initial period following the incident, and combined with avoidance of tight dressings or constriction. The or must not be removed until a full is completed, as premature removal could lead to continued leakage from the puncture site. The healthcare provider or should be notified immediately in accordance with institutional protocols, ensuring prompt evaluation and documentation of the event to guide further management.

Specific Interventions

Specific interventions for extravasation are tailored to the type of infused agent, with vesicants requiring antidotes to mitigate severe tissue damage and irritants managed through topical agents and thermal therapy. For vesicant extravasations, dexrazoxane serves as the primary antidote for anthracyclines such as doxorubicin, daunorubicin, epirubicin, and idarubicin, administered intravenously over 1-2 hours in a remote vein within 6 hours of the event to chelate the drug and reduce necrosis risk. The standard regimen is 1000 mg/m² on day 1 (maximum 2000 mg), 1000 mg/m² on day 2 (maximum 2000 mg), and 500 mg/m² on day 3 (maximum 1000 mg). For vinca alkaloids like vincristine, hyaluronidase is injected subcutaneously in a pentagon pattern around the site (150-250 units, maximum 250 units) to hydrolyze hyaluronic acid and facilitate dispersion of the extravasated fluid, thereby limiting localized toxicity. In cases of irritant extravasation, topical (DMSO) at 99% concentration is applied as four drops per 10 cm² over an area twice the size of the extravasation site to penetrate tissues and neutralize the agent, though it should not be combined with due to potential interference with efficacy. 1% cream is also used topically every 6 hours for up to 7 days to reduce and . Thermal compresses are agent-specific: warm compresses (15-20 minutes, four times daily for 24 hours) for alkaloids and vasopressors to promote absorption, and cold compresses (15-20 minutes, four times daily) for taxanes and to constrict vessels and minimize spread. Surgical interventions are reserved for grade 3 or higher extravasations involving significant ulceration or , where options include to remove necrotic tissue or the saline washout technique, which involves multiple incisions and with normal saline under to flush out the extravasated material within 24-48 hours. These recommendations stem from 2020s guidelines by the Oncology Nursing Society (ONS)/ (ASCO) and the Infusion Nurses Society (INS), which emphasize agent-specific approaches despite the scarcity of high-quality randomized controlled trials, relying instead on expert consensus and observational data.

Complications

Acute Complications

Acute complications of extravasation vary by the agent; non-vesicant fluids (e.g., normal saline or hypotonic solutions) typically cause mild, self-limited infiltration with localized pain, swelling, and that resolve within days without intervention. In contrast, vesicant agents trigger more severe responses. Acute complications from vesicants arise shortly after the event, typically within hours to days, and encompass immediate inflammatory and destructive responses at the site of fluid leakage into surrounding tissues. These effects are driven by the chemical properties of the extravasated agents, such as vesicants used in , which trigger rapid local reactions including pain, swelling, and . Local effects often involve secondary at the extravasation due to compromised barriers, potentially leading to formation or that requires prompt intervention to prevent spread. Such infections exacerbate initial swelling and induration, increasing the risk of deeper tissue involvement if not addressed. For non-vesicants, infection risk is lower but possible with large volumes or poor . Tissue damage manifests as blistering that can progress to ulceration, particularly with irritant or vesicant agents, resulting in localized and sloughing of skin. Large-volume extravasations, for instance from hypertonic solutions or irrigation fluids, may induce by elevating intracompartmental pressure, compromising blood flow and necessitating urgent decompression to avert irreversible ischemia. Non-vesicant hypertonic solutions (e.g., 10% dextrose) can occasionally cause similar pressure effects but rarely require surgery. Functional impairments are common in extremity extravasations, where severe pain and limit mobility and daily activities, often requiring multimodal strategies including analgesics and elevation. Milder cases from non-vesicants may only need . The of progressing to ulceration is notably higher with vesicants, with approximately one-third of such extravasation events leading to this outcome according to clinical series.

Chronic Complications

Chronic complications of extravasation also depend on the agent; non-vesicant extravasations rarely lead to long-term issues, resolving fully in most cases, whereas vesicant agents, particularly chemotherapeutic drugs, result in progressive and irreversible tissue damage, often necessitating long-term medical intervention. Severe cases can lead to extensive scarring and , where repeated cycles of and impaired cause induration that persists for months, potentially requiring surgical excision or to prevent further deterioration. Approximately one-third of vesicant extravasations progress to ulceration, exacerbating and resulting in contractures that limit and limb , especially in with pre-existing circulatory compromise. may also develop in affected limbs due to lymphatic disruption, particularly following extravasation in areas with impaired drainage, such as post-mastectomy sites, leading to chronic swelling and increased infection susceptibility. These changes often manifest as cosmetic deformities, including permanent discoloration, asymmetry, or tissue loss, which can profoundly affect daily activities and self-perception. Nerve involvement represents another enduring consequence, with vesicant exposure capable of inflicting direct that manifests as chronic neuropathy or sensory deficits. Patients may experience persistent numbness, tingling, weakness, or in the affected area, stemming from damage to underlying and tendons, which can extend beyond the initial site of injury. In vulnerable populations, such as those with or pre-existing , sensory loss heightens the risk of undetected extravasation and prolongs recovery, sometimes resulting in irreversible neurologic impairments that require ongoing neurological monitoring. The psychological toll of these chronic sequelae is significant, often compounded by visible scarring or functional limitations that erode and . Patients frequently report heightened anxiety, distress, and fear of recurrence, which can deter adherence to future treatments and necessitate multidisciplinary support. plays a crucial role in mitigating these effects, with aimed at restoring mobility through stretching and strengthening exercises to counteract contractures and . Psychological interventions, including counseling, are essential for addressing concerns, particularly in visible sites like the or , helping patients cope with and rebuild emotional .

References

  1. [1]
    Extravasation: Symptoms, Causes & Treatment - Cleveland Clinic
    Extravasation is the leakage of blood, lymph or other fluid, such as an anticancer drug, from a blood vessel or tube into the tissue around it.Missing: reliable sources
  2. [2]
    Guidelines for the management of extravasation - PMC
    Aug 10, 2020 · Extravasation is the leakage of an injected drug out of the blood vessels, damaging the surrounding tissues. In terms of cancer therapy, ...Missing: reliable | Show results with:reliable
  3. [3]
    ONS/ASCO Guideline on the Management of Antineoplastic ...
    Sep 18, 2025 · Extravasation is an uncommon but high-risk adverse event that occurs when an agent with the potential to cause tissue damage leaks out of the ...Missing: sources | Show results with:sources
  4. [4]
    Definition of extravasation - NCI Dictionary of Cancer Terms
    The leakage of blood, lymph, or other fluid, such as an anticancer drug, from a blood vessel or tube into the tissue around it.
  5. [5]
    What are current recommendations for treatment of drug ...
    Feb 2, 2021 · Extravasation is defined as the leakage or inadvertent administration of a vesicant drug or solution from a vein into the extravascular space.Missing: reliable | Show results with:reliable
  6. [6]
    extravasation, n. meanings, etymology and more
    OED's earliest evidence for extravasation is from 1676, in the writing of Richard Wiseman, surgeon. extravasation is formed within English, by derivation.
  7. [7]
    EXTRAVASATION definition in American English - Collins Dictionary
    Word origin. [1670–80; extravasate + -ion]This word is first recorded in the period 1670–80. Other words that entered English at around the same time include ...Missing: etymology | Show results with:etymology
  8. [8]
    IV Therapy: The Difference between Infiltration and Extravasation
    If extravasation occurs, it means that an accidental infiltration of a vesicant or chemotherapeutic drug into the surrounding IV site has occurred. Vesicants ...
  9. [9]
    Infiltration vs Extravasation in IV Therapy - Simple Nursing
    Mar 12, 2023 · Unlike infiltration, which involves the leakage of non-irritating fluids or medications, extravasation can cause significant tissue damage and ...
  10. [10]
    Infiltration and Extravasation Care (including the use of ...
    The difference between an infiltration and extravasation is the type of medicine or fluid that is leaked. Infiltration – if the fluid is a non-vesicant (does ...
  11. [11]
    Extravasation: Definition, symptoms, and treatment
    Jun 29, 2021 · Extravasation occurs when IV medications, which can destroy tissue, seep out of veins and into the surrounding skin and muscle.
  12. [12]
    Extravasation Injuries in Adults - PMC - PubMed Central
    Extravasation injury is defined as the damage caused by the efflux of solutions from a vessel into surrounding tissue spaces during intravenous infusion.Missing: sources | Show results with:sources
  13. [13]
    [PDF] Overview of the Pathophysiology of Extravasation of Anesthetic Drugs
    Mar 1, 2023 · While extravasation injury has been reported with high doses of dopamine and dobutamine, tissue necrosis has rarely been reported with low doses ...
  14. [14]
    Peripheral venous extravasation injury - PMC - NIH
    Various symptoms and signs can indicate extravasation. Tenderness, discomfort, swelling, taut skin, induration, leakage of fluid, blanching, erythema, fixed ...Management · Evolving Tissue Injury Risk... · Figure 1
  15. [15]
    Management of noncytotoxic extravasation injuries: A focused ...
    Mar 20, 2023 · Physiochemical causes of tissue injury include vasoconstriction, pH-mediated, osmolar-mediated, and cytotoxic mechanisms of extravasation ...4.1 Vasopressors · 4.3 Osmotically Active... · 5 Pharmacological Treatment...
  16. [16]
    Management of Chemotherapy Extravasations - U.S. Pharmacist
    Sep 21, 2009 · Pathophysiology of Tissue Damage. The extent of tissue damage depends on the chemotherapeutic agent's binding capacity to DNA. DNA-binding ...
  17. [17]
    Intravenous contrast medium extravasation: systematic review and ...
    Feb 17, 2022 · In this paper, we review the literature pertaining to the pathophysiology, diagnosis, risk factors and treatments of contrast media extravasation.
  18. [18]
    Exploring Extravasation in Cancer Patients - PMC - PubMed Central
    Extravasation of chemotherapy drugs and radiation therapy can cause tissue damage through multiple mechanisms, including chemical toxicity, vascular injury, ...
  19. [19]
    Fluid Extravasation in Shoulder Arthroscopic Surgery: A Systematic ...
    May 14, 2018 · Fluid extravasation has the potential to be a life-threatening complication of shoulder arthroscopic surgery; however, it is most commonly managed ...
  20. [20]
    Urethral Injury - StatPearls - NCBI Bookshelf - NIH
    Jul 24, 2023 · Urethral injuries are a relatively rare process that is often associated with severe trauma, childbirth, and improper catheterization.Etiology · History and Physical · Evaluation · Treatment / Management
  21. [21]
    Pathophysiology and clinical manifestations of immune complex ...
    Mar 3, 2023 · Clinically, the inflammatory infiltrates and ensuing extravasation of blood manifests as hemorrhagic maculae, papules, and plaques, sometimes in ...
  22. [22]
    Extravasation Risk Using Ultrasound Guided Peripheral Intravenous ...
    Patients who received contrast for a CT scan through an USGIV had a higher risk of extravasation than those who received contrast through a standard peripheral ...Missing: causes | Show results with:causes
  23. [23]
    Chemotherapy Extravasation: Incidence of and Factors Associated ...
    Dec 1, 2021 · Incidence rates for both settings were 0.001%. The most common agent to extravasate was docetaxel, and all events occurred via peripheral route.
  24. [24]
    Describing Intravenous Extravasation in Children (DIVE Study) - PMC
    Identified risk factors in patients of all ages include insertion of the cannula and administration of the medication by inexperienced staff; venipuncture and ...
  25. [25]
    Peripheral intravenous therapy infiltration and extravasation (PIVIE ...
    Oct 9, 2024 · The results indicated that sex, age, disease classification, puncture site and indwelling time were identified as risk factors for the occurrence of PIVIE.
  26. [26]
    Describing Intravenous Extravasation Injuries in Children (DIVE2 ...
    Pharmacologic factors contributing to the risk of extravasation injury include pH (< 5 or > 9), osmolarity (< 281 mOsm/L or > 350 mOsm/L), vasoconstrictive ...
  27. [27]
    Extravasation of Antineoplastic Agents: Prevention and Treatments
    Left untreated, vesicant chemotherapy extravasation can potentially cause tissue necrosis, functional impairment and permanent disfigurement. This article ...
  28. [28]
    An update on extravasation: basic knowledge for clinical pharmacists
    Apr 27, 2020 · Extravasation is the leakage of intravenously administered solution into surrounding tissues, which can cause serious damage to the patient.Missing: sources | Show results with:sources
  29. [29]
    Fluid Extravasation Related to Hip Arthroscopy - PubMed Central - NIH
    Mar 12, 2015 · 10% of the infused volume was extravasated in uncomplicated hip arthroscopy. Risk factors for extravasation were related to operative time.
  30. [30]
    Abdominal compartment syndrome during hip arthroscopy for ... - NIH
    May 8, 2017 · A recent study has suggested that extravasation of irrigation fluid after hip arthroscopy may be a common complication (16% incidence), and that ...
  31. [31]
    Vancomycin - StatPearls - NCBI Bookshelf - NIH
    Vancomycin irritates tissue and must be administered using a secure intravenous route to reduce the risk of local irritation and phlebitis. Thrombophlebitis ...
  32. [32]
    The Prevalence and Associated Factors of Peripheral Intravenous ...
    Mar 6, 2024 · 2 Infiltration is the leakage of fluid out of the vein, and extravasation is the leakage of a vesicant drug out of the vein. Phlebitis, caused ...
  33. [33]
    [PDF] Chemotherapy Extravasation - Oncology Nursing Society
    Depending on the potential for causing tissue damage, drugs are classified as vesicants, irritants with vesicant properties (IVPs), irri- tants, exfoliants ...
  34. [34]
    Contrast media extravasation injury: a prospective observational ...
    Oct 25, 2023 · Risk factors for moderate contrast media extravasation injury are malignant tumors, iohexol, large-volume (> 50 mL) extravasation, and back-of-the-hand ...
  35. [35]
    Extravasation of radiographic contrast material and compartment ...
    Extravasation of contrast is a possible complication of imaging studies performed with contrasts. Most extravasations cause minimal swelling or erythema, ...
  36. [36]
    Extravasation of Concentrated Potassium Chloride: A Case Report
    Intravenous infusion of potassium chloride can cause dehydration, hypoxia, congestion, and edema of vascular endothelial cells, causing vasoconstriction and ...
  37. [37]
    55. EXTRAVASATION - Journal of Infusion Nursing
    Extravasation should always be rated Grade 4 on the Infiltration Scale (see Standard 54, Infiltration). When using the standard scale to document extravasation ...
  38. [38]
    [PDF] Infiltration Scale - QI EQUIP
    Grade. Clinical Criteria. 0. No symptoms. 1. Skin blanched. Edema < 1 inch in any direction. Cool to the touch. With or without pain. 2. Skin blanched.
  39. [39]
    A Trivial Injury Often Overlooked with Disastrous Consequences - NIH
    The soft tissue injury that occurs as a result of the extravasate is related to 4 factors including osmolarity, inherent cytotoxicity, infusion pressure, and ...Missing: rupture | Show results with:rupture
  40. [40]
    New Extravasation Guidelines Provide Recommendations for ...
    Oct 21, 2025 · The guidelines include an algorithm that incorporates discovery, management, and follow-up care (see sidebar) as well as a grading scale for ...
  41. [41]
    IV Infiltration and Extravasation: Causes, Signs, Side Effects ...
    May 27, 2020 · IV infiltrations and extravasations occur when fluid leaks out of the vein into surrounding soft tissue. Common signs include inflammation, tightness of the ...
  42. [42]
    IV Infiltration Can Cause Nerve Damage, Burns, or Amputation
    Mar 20, 2023 · When infused fluid enters surrounding tissue, it can compress or damage the nerves, leading to symptoms such as numbness and tingling in the ...Missing: extravasation compression edema
  43. [43]
    Chemotherapy Extravasation Causing Soft-Tissue Necrosis ...
    Mar 1, 2024 · This can cause severe tissue damage, leading to cellulitis, which may progress to myositis. Treatment typically involves wound debridement.
  44. [44]
    Chapter 2 Administer IV Push Medications - Nursing Advanced Skills
    Any time a medication or fluid is given into an IV site, there is increased risk for complications such as infiltration, extravasation, and phlebitis. Review ...Missing: tingling | Show results with:tingling
  45. [45]
    Sensing Technologies for Extravasation Detection: A Review - PMC
    Extravasation happens when the catheter is not properly inserted into the vessel or unintentionally directed outside of the vein due to movement of the patient ...Missing: rupture | Show results with:rupture<|separator|>
  46. [46]
    Usefulness of magnetic resonance imaging for surgical ... - PubMed
    We believe that MR imaging is useful for estimating deep tissue damage due to extravasation of an antitumor agent. ... Extravasation of Diagnostic and Therapeutic ...Missing: assessing | Show results with:assessing
  47. [47]
    Utility of laboratory markers in evaluating for acute compartment ...
    Dec 12, 2020 · Serum creatinine kinase (CK) levels >4000 U/L, chloride (Cl) levels >104 mg/dL, and blood urea nitrogen (BUN) levels <10 mg/dL were found to ...
  48. [48]
    Summary of Recommendations | Infection Control - CDC
    Feb 28, 2024 · 3. Wear clean gloves, rather than sterile gloves, for the insertion of peripheral intravascular catheters, if the access site is not touched ...<|control11|><|separator|>
  49. [49]
    Peripheral Line Placement - StatPearls - NCBI Bookshelf - NIH
    The line is supplied pre-loaded over a hollow, laser-sharpened, beveled needle with a transparent "flashback" chamber at its opposite end. This allows the ...
  50. [50]
    Chapter 1 Initiate IV Therapy - Nursing Advanced Skills - NCBI - NIH
    The client's upper extremities (hands and arms) are the preferred sites for insertion. However, a potential limitation of using the hand veins is they are ...
  51. [51]
    Peripheral intravenous catheter securement: An integrative review of ...
    Feb 3, 2022 · This review found nonsterile tape was associated with increased failure and complications; multiproduct dressing and securement bundles were prevalent.
  52. [52]
    Intravenous Cannulation Technique - Medscape Reference
    Apr 17, 2023 · Small superficial veins are best accessed by using a small catheter (22-24 gauge) placed at a 10-25º angle. Deeper veins should be accessed with ...
  53. [53]
    [PDF] Extravasation - MD Anderson Cancer Center
    1Unintentional instillation, leakage, passage or escape of a vesicant out of a blood vessel into surrounding tissue. This may result in varying degrees of ...
  54. [54]
    [PDF] UNC Lineberger Cancer Network
    Jun 21, 2023 · Discuss risks of extravasation and tissue damage with patients prior to start of treatment. • Assess patient difficulty with obtaining ...Missing: Society | Show results with:Society
  55. [55]
    Moving from Reactive to Proactive IV Safety: Why INS Standards Are ...
    May 27, 2025 · For example, the Standards recommend visual inspection and palpation of IV sites and note that assessment frequency should be tailored to the ...
  56. [56]
    ONS/ASCO Guideline on the Management of Antineoplastic ...
    Implications for Nursing: This guideline summarizes evidence-based interventions for the management of extravasation of antineoplastic vesicants or irritants ...Missing: 2023 | Show results with:2023
  57. [57]
    ONS/ASCO Guideline on the Management of Antineoplastic ...
    Sep 17, 2025 · This guideline summarizes evidence-based interventions for the management of extravasation of antineoplastic vesicants or irritants with ...Missing: 2023 | Show results with:2023
  58. [58]
    Overview, prevention and management of chemotherapy ...
    Factors related to chemotherapeutic agent itself and that increase the risk of chemotherapy extravasation include the vesicant properties of the drug, its ...
  59. [59]
    [PDF] GUIDELINE FOR MANAGEMENT OF EXTRAVASATION
    for 30 minutes and apply hydrocortisone cream 1% every 6 hours for 7 days or as long as erythema persists). should be applied within 10-25 minutes • Apply a ...
  60. [60]
    A Primer on the Acute Management of Intravenous Extravasation ...
    Apr 19, 2018 · Hyperosmolar solutions cause a fluid shift from vascular and cellular compartments into the surrounding tissues leading to elevated compartment ...
  61. [61]
    [PDF] What is the optimal approach to infiltration and extravasation of ...
    May 5, 2023 · In extreme cases, surgical debridement, skin-grafting, or even amputation may be required. In this article, we will use the terms extravasation.
  62. [62]
    Infusion Therapy Standards of Practice - INS
    The Infusion Therapy Standards of Practice promotes consistency in patient care, guides clinical decision-making, and enhances competency.
  63. [63]
    Analysis of a US Hospital Discharge Database - PubMed Central
    Sep 15, 2019 · Complications include bloodstream infection, upper extremity cellulitis and abscess, upper extremity superficial phlebitis and thrombophlebitis ...
  64. [64]
    Compartment syndrome due to extravasation of peripheral ...
    We report a rare case of compartment syndrome and skin necrosis due to extravasation, requiring emergency fasciotomy and skin graft in a 7-month-old boy.Missing: induced | Show results with:induced
  65. [65]
    Extravasation Reactions - Holland-Frei Cancer Medicine - NCBI - NIH
    Extravasation injury is a well-known adverse event that occurs when offending drugs escape from the veins or intravenous catheters into subcutaneous tissues.Missing: definition | Show results with:definition